Avantax Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Avantax Advisory Services's NBIX Position: Q2 2025 in Review
Avantax Advisory Services increased its Neurocrine Biosciences (NBIX) stake by 57% in Q2 2025, buying an estimated $139K and bringing the position to 3,325 shares worth $418K. The position accounts for ﹤0.01% of the portfolio, ranked #1690.
Avantax Advisory Services first reported a position in NBIX in Q2 2024 and has held it in 5 quarters since. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.
- Avantax Advisory Services held 3,325 shares of Neurocrine Biosciences worth $418K as of Q2 2025.
- Avantax Advisory Services bought 1,213 Neurocrine Biosciences shares in Q2 2025, an estimated $139K.
- Neurocrine Biosciences made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #1690 holding.
- Avantax Advisory Services first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 5 quarters since.
- 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.
Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.